Capecitabine is a new, orally administered precursor of 5'-deoxy-5-fluorouridine (5'-DFUR) that is preferentially transformed into its active catabolite owing to a higher intratumoral expression of the activating enzyme thymidine phosphorylase. In a randomized phase II study by O'Shaughnessy et al, capecitabine was administered as first line with CMF (cyclophosphamide/methotrexate/5-fluorouracil [5-FU]) as a reference arm in patients aged ≥ 55 years. 1 In this study, 93 patients were randomized to receive capecitabine 1255 mg/m 2 twice daily (for 14 days with 7 days of rest) or intravenous (I.V.) CMF; the response rate (RR) was 30% with capecitabine and 16% with CMF; survival was similar in the 2 treatment groups (19.6 months with capecitabine and 17.2 months with CMF). In the capecitabine arm, grade 3/4 toxicities were as follows: palmar-plantar erythrodysesthesia (PPE) occured in
15% of patients, diarrhea in 8%, stomatitis in 8%, asthenia and fatigue in 8%, vomiting in 5%, and neutropenia in 10% (3 toxic-related deaths were reported: 2 possibly and 1 probably related). The authors concluded that capecitabine at 1255 mg/m 2 twice daily is effective and well tolerated when used as first-line chemotherapy in older patients even if treatment interruption and/or individual adjustment of capecitabine dose was required in 34% of patients. Similar results in terms of RRs and toxicity were reported in pretreated patients by Fumoleau et al 2 and Blum et al 3 . In the Fumoleau trial, 126 anthracyclines/taxane-pretreated patients were treated with capecitabine 1250 mg/m 2 twice daily; an objective RR of 28% was exhibited; the main adverse events leading to dose reduction were PPE (n = 22), neutropenia (n = 10), and diarrhea (n = 7). In the Blum study, 74 taxane-pretreated patients were treated with the same standard dose of capecitabine, reporting an overall RR (ORR) of 26%; grade 3/4 toxicities including PPE in 22% of patients, diarrhea in 16%, asthenia/fatigue in 8%, vomiting in 4%, and neutropenia in 1 patient (no toxicrelated death was reported). To overcome these side effects, the capecitabine dose was reduced to 1000 mg/m 2 twice daily in a phase II study by El-Helw et al with an ORR of 28% (29% in 17 anthracyclines/taxane-pretreated patients) and a better toxicity profile. 4 The same activity at this lower dose was documented even in elderly patients by Bajetta et al with an RR of 34.9% 5 ; grade 3/4 adverse events were very low: PPE in 2% of patients, diarrhea in 2%, and neutropenia in 2%. The aim of our study was to confirm capecitabine safety and activity at the dose of 1000 mg/m 2 twice daily for 14 days followed by 7 days of rest.
Patients and Methods

Eligibility Criteria
Thirty-seven patients with histologically proven breast cancer and metastatic disease were enrolled in this study. Chemotherapy-naive patients or patients with a previous chemotherapy schedule for advanced disease were eligible for the study. Other selection criteria included: Eastern Cooperative Oncology Group performance status 0-2; adequate renal, liver, and bone marrow function; and a life expectancy of ≥ 3 months. Previous radiation therapy was accepted if measurable lesions were present in a nonirradiated area; patients with symptomatic brain metastases were excluded from the study. Staging procedures included physical examination, chest radiograph or chest computed tomography (CT) scan, liver ultrasonography or liver CT scan, and bone scan (brain CT scan was performed if clinically indicated). Patients repeated the same type of assessment at any disease evaluation. Written informed consent was obtained from all patients.
Study Design and Statistical Methods
Patients were treated with capecitabine 1250 mg/m 2 twice daily for 14 days followed by 7 days of rest until 3 episodes of grade 3 toxicity was documented; then, all of the next patients were treated with 1000 mg/m 2 twice daily. The aim of this study was safety and activity of capecitabine at this lower dose. Response to therapy was assessed according to World Health Organization standard criteria 6 after ≥ 4 cycles at the same time with the same type of baseline imaging. Toxicity was evaluated every cycle according to National Cancer Institute criteria. Time to progression (TTP) was calculated as the interval between day 1 of the first cycle and first documentation of progression; overall survival (OS) was calculated as the interval between day 1 of the first cycle and the date of death or, in absence of its assessment, last followup. Median TTP and median survival were calculated according to the Kaplan-Meier method (all patients have been included in the analysis). According to the optimal 2-stage design, for a target activity level of ≥ 40% (p1-p0 = .20) with capecitabine as first line, 3 responses had to be documented after 13 patients (error probability limits, .05 and .2); for a target activity level of ≥ 25% (p1-p0 = .2) with capecitabine in pretreated patients, 2 responses had to be documented after 17 patients (error probability limits, .05 and .2).
Results
Patient Population
Thirty-seven patients with advanced breast cancer entered the study: the first 7 patients were treated with capecitabine 1250 mg/m 2 twice daily and the following 30 with capecitabine 1000 mg/m 2 . Median age was 62 years (range, 38-87 years); 322 cycles were administered with a median of 9 cycles (range, 1-35 cycles). Thirteen patients were chemotherapy naive and 24 were pretreated with chemotherapy (9 patients, 1 line; 15 patients, ≥ 2 lines); 34 of 37 patients were pretreated with ≥ 1 hormonal line (27 patients with ≥ 2 lines). Soft tissue metastases were documented in 36
Safety Profile and Activity of Lower Capecitabine Dose in MBC 
Safety
All patients were evaluable for toxicity. Overall toxicities were as follows: PPE in 9 patients (grade 3 in 5 patients [13.5%]), asthenia in 7 patients (grade 3 in 4 patients [11%]), vomiting in 4 patients (grade 3 in 1 patient [2.7%]), grade 2 renal toxicity in 1 patient (2.7%), and grade 2 skin reaction in 1 patient (2.7%; Table 1 ). No episodes of grade 2/3 neutropenia or other hematologic toxicity were reported; no toxic-(possibly or probably) related death was documented; 1 patient showed a suspected cardiac toxicity. Palmar-plantar erythrodysesthesia was reported at the dose of 1000 mg/m 2 twice daily in 8 of 9 patients (3 patients with grade 2 and 5 patients with grade 3); asthenia and vomiting was documented in 7 of 11 patients at the dose of 1250 mg/m 2 twice daily ( Table 2) . A dose reduction was required in 8 of 37 patients (21.6%): 6 at "lower" dose and 2 at "higher" dose (in 7 of 8 patients for grade 2/3 PPE). Reasons for 7 patients excluded from the analysis of response were as follows: 1 patient was admitted to the medicine unit for suspected congestive heart failure and then stopped capecitabine; 1 patient stopped capecitabine after the first cycle for creatinine increase (grade 2 renal toxicity), and then refused to continue oral therapy; 1 patient refused to complete the planned 4 cycles; 1 patient stopped chemotherapy due to a number of side effects (grade 3 asthenia and vomiting and severe anorexia) after 3 cycles and was admitted to our oncology unit for supportive care; 3 patients discontinued chemotherapy after the first cycle for "poor" compliance in the administration of tablets. To date, 2 patients are still receiving treatment and 1 patient had received 35 capecitabine cycles by December 2003.
Efficacy
Thirty patients were evaluable for response (5 patients at "higher" dose, 25 patients at "lower" dose). The ORR was 57% (5 CRs and 12 PRs); 95% CI, 39%-74%; stable disease (after 24 weeks) 20% and progressive disease 23%. Eight of 13 chemotherapy-naive patients (61.5%) and 9 of 24 pretreated patients (37.5%) responded to capecitabine, according to the intent-to-treat principle (6 of 9 patients had visceral metastases). Three of 5 patients responded at the "higher" dose (all in pretreated patients, 60%) and 14 of 25 patients responded at the "lower" dose (56%, 8 responses in chemotherapy-naive and 6 responses in pretreated patients; Table 3 ). Median TTP was 7 months (range, 1-38 months; Figure 1 ), and median OS was 19 months (range, 2-47 months; Figure 2 ).
Discussion
Breast cancer is one of the most common malignancies affecting women in the world. 7, 8 Nearly half of these women develop metastatic disease 9 ; for patients with hormone-
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Response and Survival Results Table 3 Evaluable for Toxicity Safety Profile and Activity of Lower Capecitabine Dose in MBC resistant, hormone receptor-negative, or rapidly disseminating disease, chemotherapy is the treatment of choice. Anthracyclines and taxane schedules are widely used for their proved efficacy; otherwise, these drugs produce a number of side effects (particularly gastrointestinal, hematologic, and neurologic toxicity). Moreover, the use of these drugs has shifted toward application earlier in the course of the disease or in adjuvant setting, for high-risk populations.
To overcome typical toxicities of these drugs (maintaining similar efficacy), a new drug, capecitabine, has been designed. Capecitabine is an oral fluoropyrimidine with high activity in metastatic breast cancer (MBC); 2 clinical trials conducted in Northern Europe and in France have demonstrated that oral capecitabine is a highly effective and well-tolerated treatment for heavily pretreated MBC with an ORR of 20%-25%. 2, 10 In the O'Shaughnessy et al study, 1 capecitabine 1255 mg/m 2 twice daily (for 14 days followed by 7 days of rest) demonstrated efficacy in first-line therapy compared with I.V. CMF, with an RR of 30% versus 16%. Recently, Stockler et al confirmed these data, reporting results of a phase III study with a lower dose of capecitabine as first-line therapy 11 ; 325 women were randomized to receive capecitabine 2000 mg/m 2 every day (intermittently for 14 days with 7 days of rest), or capecitabine 1300 mg/m 2 every day (continuously for 21 days of every 21 days), or classical CMF. Response rates were similar on the capecitabine arm and CMF (21% vs. 18%); however, OS was longer with capecitabine (median, 22 months vs. 18 months). Moreover, capecitabine was less toxic and more tolerable than CMF (no other safety details have been published on abstract). Bajetta et al demonstrated the same efficacy in older patients with the dose of 1000 mg/m 2 twice daily, for 14 days every 21 days. 5 In this trial, patients who received previous chemotherapy showed an RR of 28%, whereas patients without cytotoxic pretreatment exhibited an RR of 38%. In another small trial by El-Helw et al, the authors obtained an ORR of 28% (29% in 17 anthracycline/taxane-pretreated patients) with the same capecitabine schedule. 4 We started our trial with the "standard" dose of 1250 mg/m 2 twice daily for 14 days with 7 days of rest, until 3 episodes of grade 3 toxicity occurred. Then, the protocol planned to reduce the dose to 1000 mg/m 2 twice daily, and the aim of the study was to confirm safety and activity of this lower capecitabine dose. In our study, the RR in chemotherapy-naive patients was higher than reported by other authors, particularly by O'Shaughnessy and Stockler, (61.5% vs. 30% and 21%, respectively) but we must take into account the small number of treated patients (13 vs. 61 and 214) and the number of patients with visceral metastases (only 4 of 13 patients, 30.7%). However, we emphasize that we were able to deliver a median of 13 cycles in responding patients that could have been a determining factor for the better response in the low-dose group (in the O'Shaughnessy et al study, the median duration of treatment was only of 4 cycles).
When we analyze the RR in pretreated patients (24%, 6 of 25 evaluable patients), this result is satisfactory, considering that 22 of 24 patients received anthracyclines and/or taxane schedules. These data confirmed capecitabine activity at a lower dose (1000 mg/m 2 twice daily for 14 days followed by 7 days of rest) reported by Bajetta et al, with an RR of 34.9% and an overall benefit rate, complete response plus partial response plus stable disease > 24 weeks, of 60%. 5 When we compared the safety of the "lower" dose with the "higher" dose, we emphasize the more favorable profile of the lower dose, except for PPE (16.6% of grade 3 episodes) and asthenia (6.6% of grade 3 episodes). Diarrhea, stomatitis, vomiting, and neutropenia were more frequent with the higher dose (Table 4) . 1, 3 Moreover, in our trial we were able to administer capecitabine for a long time with the lower dose (median of 13 cycles), although a dose reduction was required in 6 patients, just for grade 2/3 PPE. In addition, no toxicity-related (possibly or probably) death was reported (in the O'Shaughnessy et al study, 3 toxic deaths occurred).
Conclusion
Our study confirmed activity and favorable safety profile of lower capecitabine dose in chemotherapy-naive and pretreated patients with breast cancer allowing long treatments (10 patients received > 10 cycles) with less toxicity. 
Grade 3/4 Treatment-Related Side Effects in 3 Studies
